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Abstract
Background: Extracellular matrix degrading proteases and their regulators play an important role in atherogenesis and
subsequent plaque rupture leading to acute cardiovascular manifestations.
Design and methods: In this prospective cohort study, we investigated the prognostic value of circulating matrix
metalloproteinase-8, tissue inhibitor of matrix metalloproteinase-1 concentrations, the ratio of matrix metalloprotei-
nase-8/ tissue inhibitor of matrix metalloproteinase-1 and, for comparison, myeloperoxidase and C-reactive protein
concentrations for incident cardiovascular disease endpoints. The population-based FINRISK97 cohort comprised
7928 persons without cardiovascular disease at baseline. The baseline survey included a clinical examination and
blood sampling. During a 13-year follow-up the endpoints were ascertained through national healthcare registers.
The associations of measured biomarkers with the endpoints, including cardiovascular disease event, coronary artery
disease, acute myocardial infarction, stroke and all-cause death, were analysed using Cox regression models.
Discrimination and reclassification models were used to evaluate the clinical implications of the biomarkers.
Results: Serum tissue inhibitor of matrix metalloproteinase-1 and C-reactive protein concentrations were associated
significantly with increased risk for all studied endpoints. Additionally, matrix metalloproteinase-8 concentration was
associated with the risk for a coronary artery disease event, myocardial infarction and death, and myeloperoxidase
concentration with the risk for cardiovascular disease events, stroke and death. The only significant association for the
matrix metalloproteinase-8/ tissue inhibitor of matrix metalloproteinase-1 ratio was observed with the risk for myo-
cardial infarction. Adding tissue inhibitor of matrix metalloproteinase-1 to the established risk profile improved risk
discrimination of myocardial infarction (p¼0.039) and death (0.001). Both matrix metalloproteinase-8 (5.2%, p< 0.001)
and tissue inhibitor of matrix metalloproteinase-1 (12.9%, p< 0.001) provided significant clinical net reclassification
improvement for death.
Conclusions: Serum matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 can be considered
as biomarkers of incident cardiovascular disease events and death.
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Systemic inflammation is a key contributing factor in
atherosclerosis, which underlies cardiovascular diseases
(CVD).1 Myocardial infarction (MI) and ischaemic
stroke, the acute and often fatal complications of
CVD, account for one-third of the deaths worldwide.2
These complications result from plaque rupture or
thrombus formation in the arterial tree and are shaped
largely in concert by various inflammatory mediators.
Although risk factors have been mapped extensively,
these events are difficult to predict since they often
occur without prior symptoms. Therefore, finding spe-
cific biomarkers that can predict the outcomes and iden-
tify patients at risk would be highly valuable.
Matrix metalloproteinases (MMPs) play a critical
role in inflammatory processes and are capable of
degrading almost all extracellular proteins.3 MMPs
are secreted by inflammatory cells, in concert with
endothelial and smooth muscle cells. They facilitate
leukocyte navigation through the extracellular matrix
(ECM) and modify immune responses and blood pres-
sure by processing of non-matrix bioactive sub-
strates.3,4 In ex vivo studies, MMP-8 levels are shown
to be higher in vulnerable plaques when compared to
normal arteries.5 ECM modulation by MMPs increases
the vulnerability of the atherosclerotic plaque signifi-
cantly.6 MMPs have been shown to localise in the
coronary atheroma shoulder regions – the areas espe-
cially prone to rupture leading to subsequent luminal
thrombosis.7 Disturbances in the regulation of MMP-8
have also been linked to plaque formation and matur-
ation.8–11 Previous reports showed that serum MMP-8
is associated with prevalent coronary artery disease
(CAD) and acute coronary syndrome (ACS), and also
with future CVD events in men and in a general popu-
lation with no CVD at the baseline.12–15
The balance between pro- and anti-degradative fac-
tors determine the integrity of the atherosclerotic
plaque ECM. The key regulators of MMP activity are
tissue inhibitors of matrix metalloproteinases (TIMPs),
TIMP-1 being the most potent and well-studied of the
four major endogenous inhibitors.16 TIMP-1 has also
been reported as an independent predictor of CVD
events and cardiac death.17,18 The imbalance between
MMP-8 and TIMP-1 may indicate vulnerability of the
atherosclerotic plaque to rupture.13
The aim of our study was to evaluate the prognostic
value of serum MMP-8 and TIMP-1 concentrations,
and their ratio for various cardiac endpoints and
death. Myeloperoxidase (MPO) and the classical
inflammatory marker C-reactive protein (CRP) were
both included as reference values. We hypothesise
that both MMP-8 and TIMP-1 are significantly asso-
ciated with the risk of CVD events and that both can
improve the discrimination and reclassification of the
current general cardiovascular risk profile.
Methods
Study population
This study is based on the FINRISK97 Study, a
national population-based cohort (n¼ 8446) with
25–74 year-old subjects.19 The study was approved by
the Ethics Committee of the National Public Health
Institute and carried out according to the recommen-
dations of the Declaration of Helsinki. Written
informed consent was obtained from all subjects.
Data collection and study design
The subjects filled out a mailed questionnaire and parti-
cipated in a clinical examination at which blood samples
were drawn. Body mass index (BMI), systolic and dia-
stolic blood pressure, and waist/hip ratio were measured
in the clinical examination, and years of education
and smoking habits were recorded using the self-
administered questionnaires.19
Prevalent diabetes and CVD events were defined as a
doctor-diagnosed disease using the questionnaire, and in
the register data either as an intake of related drugs or as
hospitalisations with the disease. CAD events included
the history of MI, revascularisations, or percutaneous
transluminal coronary angioplasty. Additionally, history
of stroke (excluding subarachnoid haemorrhage) was
included in the prevalent CVD.
The study design was a prospective cohort study
with several endpoints (Figure 1). Some participants
with incident CVD suffered from multiple events clas-
sified as stroke, MI or CAD, thus the numbers of sub-
jects do not sum up to the number of incident CVD
events. During the 13-year follow-up (median follow-
up time 13.83, years 1997–2012; interquartile range
(IQR) 0.115), the endpoints were ascertained through
record linkage of the FINRISK data with the National
Causes of Death Register and the National Hospital
Discharge register, and they included: (a) CVD, (b)
CAD, (c) MI, (d) stroke, and (e) all-cause death. The
register derived endpoints have been shown to be valid
indicators for cardiovascular and stroke events.20,21
Serum and plasma determinations
The blood sample collection was made in public health
centres and other survey sites. In the invitation letter,
the participants were asked to fast at least for four
hours and to avoid heavy meals before the sampling.
The baseline laboratory measurements included serum
total and high-density lipoprotein (HDL) cholesterol,
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triglyceride (TG), high-sensitivity CRP and g-glutamyl-
transferase (g-GT) concentrations.22 Serum samples
were taken without coagulation activators.
The baseline concentrations of MMP-8, MPO and
TIMP-1 were measured according to manufacturer’s
instructions by following assays: serum TIMP-1 and
plasma MPO, chemiluminescent micro particle immuno-
assay (CMIA), Abbott, Architect i2000 and serum
MMP-8, time-resolved IFMA, Medix Biochemica,
Espoo, Finland. The interassay coefficients of variation
(CV%) of TIMP-1, MPO and MMP-8 assays were 3.1,
4.1 and 7.3%. For calculation of MMP-8/TIMP-1
molecular ratio, the concentrations were converted into
moles using MWs 65000 and 28000 g/mol for MMP-8
and TIMP-1, respectively.
Statistical analysis
The statistical analyses were performed with SPSS 23.0
for PC, and R (http://www.R-project.org). Before the
analysis CRP, MMP-8, MPO and TIMP-1 concentra-
tions were transformed with natural logarithm due to
the skewed distributions. The subjects with prevalent
CVD were excluded from the analyses. The missing
values were excluded from the statistical analysis.
In participants with incident CVD the number of miss-
ing values for MMP-8, TIMP-1, MMP-8/TIMP-1,
MPO and CRP were 12, 74, 76, 68 and 78, respectively.
The significance of differences in baseline characteris-
tics between the individuals without and with incident
disease during the follow-up was tested with Mann-
Whitney U-test. The differences between categorical
variables were tested with Chi-square test. In all ana-
lyses, a two-sided p-value below 0.05 was considered
statistically significant.
The associations of MMP-8, TIMP-1, MMP-8/
TIMP-1, MPO and CRP concentrations with different
endpoints were estimated by Cox proportional hazards
model using age as the time-scale. The model was
further stratified by sex and adjusted with covariates,
which were selected based on current general cardiovas-
cular risk profile presented in the Framingham Heart
Study.23 They included logarithmic total and HDL
cholesterol concentration, systolic blood pressure, use
of antihypertensive medication, smoking and prevalent
diabetes. In our population-based sample, the geo-
graphic area has been previously recognised as an
important confounder and was thus added among the
covariates.24 The socioeconomic status was monitored
by years of education, which is considered an optimal
parameter of this status in Finnish studies.25 The educa-
tion variable with three categories is a modified version
of the standard three-level education variable, which
takes into account the subjects’ age and sex, thus elim-
inating the bias caused by changes in the education
system. The assumption of proportional hazards was
assessed by extending the Cox model with a time by
biomarker interaction factor.
Finally, the potential performance improvement
added by MMP-8 and TIMP-1 in the Framingham pre-
diction model regarding MI and death was evaluated
using the C-index, net reclassification improvement
(NRI), and integrated discrimination improvement
(IDI) statistics.26 In the analyses for categorical and
clinical NRI, the subjects were assigned according
to the predicted risk to four groups (0–5%, 5–10%,
10–20%,> 20%) and three groups (0–5%,
5–20%,> 20%), respectively.27 For the 13-year absolute
risk predictions, we used 10 cross validation to reduce
overoptimism. The cross validation was stratified by sex.
Cross-validated model calibration was tested using the
Hosmer-Lemeshow goodness-of-fit test.
Results
As presented in Figure 1, 7928 subjects were free from
CVD at baseline. Of them, 89.6% survived without
registered endpoints, while 9.6, 6.7, 3.7 and 3.5% devel-
oped a CVD event, CAD event, stroke or MI, respect-
ively, and 10.4% died. The baseline characteristics of
individuals with and without registered events in the
follow-up are presented in Table 1. Subjects with a
CVD event were significantly older, and had higher
BMI, systolic blood pressure and total cholesterol con-


















Figure 1. Study design. CAD: coronary artery disease; CVD:
cardiovascular disease; MI: myocardial infarction.
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concentration. Further, they were more often men, less
educated and suffered from diabetes. A smoking habit
was significantly more frequent only in those who died
during the follow-up.
Baseline MMP-8, TIMP-1, MPO and CRP concen-
trations as well as MMP-8/TIMP-1 ratios of individ-
uals with and without different incident outcomes were
compared (Table 2). MMP-8 concentrations were sig-
nificantly lower in individuals with future CVD event
(p¼ 0.005) or stroke (p¼ 0.003). On the contrary,
TIMP-1 levels were higher in the individuals with a
future CVD outcome or death from any cause
(p< 0.001 for all). As expected, based on these concen-
trations, the MMP-8/TIMP-1 ratios were significantly
lower in individuals with incident CVD, CAD, stroke
or death (p< 0.001 for all). MPO and CRP levels were
significantly higher in individuals with any of the stu-
died outcomes (0.015< p< 0.001).
Table 3 presents multivariate associations of
continuous values of each marker (per standard devi-
ation (SD)) with incident CVD events and death
during 13-year follow-up. Serum TIMP-1 and CRP
concentrations associated significantly with increased
risk for all studied endpoints. Additionally, MMP-8
concentration was associated with the risk for a
CAD event and MI, and MPO concentration with
the risk for CVD and stroke. The only significant
association for the MMP-8/TIMP-1 ratio was
observed with the risk for MI.
The largest magnitude of risk was generally
associated with the CRP concentration; TIMP-1 con-
centration displayed higher hazard ratios (HRs) only
for stroke and death. After CRP, TIMP-1 provided
the largest HRs also for CVD and CAD events.
Risk for MI was mainly associated with MMP-8 con-
centration and its ratio with TIMP-1 with hazards of
the same magnitude.
The discrimination and reclassification of individ-
uals after addition of MMP-8 and TIMP-1 to the
Framingham risk score for incident MI and all-cause
death is shown in Table 4. The baseline model
provided C-indexes of 0.848 and 0.820 for MI and
all-cause death, respectively. Calibration for all end-
points was found successful (Hosmer-Lemeshow test;
0.60> p> 0.11).
Neither MMP-8 nor TIMP-1 concentration signifi-
cantly improved the C-index for MI. However, addition
of TIMP-1 to the baseline model for MI resulted in a
significant IDI (0.004; p¼ 0.039) and the inclusion of
correctly reclassified MI cases in the intermediate risk
category of the clinical NRI (4.6%; p¼ 0.043). MMP-8
did not produce significant NRI results for incident MI.
Inclusion of MMP-8 concentration in the model of
all-cause death did not significantly affect the C-index,
but inclusion of TIMP-1 improved it (difference 0.006;
p¼ 0.004). Both MMP-8 (5.2%, p< 0.001) and TIMP-1
(12.9%, p< 0.001) increased the number of cases clas-
sified correctly into a higher clinical risk category.
Table 1. Baseline characteristics of the participants with and without incident cardiovascular disease (CVD) in a 13-year follow-up.
No CVD Incident CVD Death
All All CAD MI Stroke All
(n¼ 7166) (n¼ 762) (n¼ 528) (n¼ 290) (n¼ 375) (n¼ 826)
Mean (SD)
Age, years 46.7 (12.9) 61.1 (9.1) 61.1 (8.7) 61.8 (8.5) 61.9 (9.4) 61.5 (10.4)
BMI, kg/m2 26.4 (4.5) 28.5 (4.3) 28.5 (4.0) 28.8 (4.1) 28.6 (4.6) 27.7 (4.8)
Systolic bp, mm Hg 134.2 (19.1) 149.2 (21.8) 148.2 (20.2) 149.6 (20.9) 150.7 (23.6) 147.5 (22.3)
Total chol, mmol/l 5.5 (1.1) 5.9 (1.1) 5.9 (1.0) 5.9 (1.1) 5.9 (1.1) 5.7 (1.1)
HDL chol, mmol/l 1.41 (0.36) 1.25 (0.33) 1.23 (0.32) 1.23 (0.34) 1.26 (0.32) 1.32 (0.37)
Education, years 11.7 (3.9) 8.9 (3.7) 8.8 (3.6) 8.5 (3.2) 8.9 (3.8) 8.9 (3.7)
n (%)
Gender, male 3345 (46.7) 536 (70.3) 387 (73.3) 205 (73.0) 198 (67.1) 554 (67.1)
Current smoker 1666 (23.2)a 183 (24.0) 125 (23.7)a 73 (27.0)a 72 (24.4)a 257 (31.1)
Prevalent DM 305 (4.3) 115 (15.1) 81 (15.3) 41 (14.6) 46 (15.6) 111 (13.4)
HTN medication 840 (11.7) 109 (14.3) 78 (14.8) 52 (18.5) 41 (13.9) 110 (13.3)
bp: blood pressure; CAD: coronary artery disease; chol: cholesterol; DM: diabetes mellitus; HDL: high-density lipoprotein; HTN: hypertension;
MI: myocardial infarction; SD: standard deviation.
All cases with prevalent CVD were excluded.
aOnly non-significant (NS) differences (no CVD versus incident CVD or death) are marked (NS: p> 0.05).
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Discussion
The present study shows that serum levels of the pro-
teolytic enzyme MMP-8 and its inhibitor TIMP-1 are
associated with increased risk for future CVD events
and death in a 13-year follow-up based on a large popu-
lation-based cohort. Inclusion of these biomarkers in
the current general cardiovascular risk profile, the
Table 2. Baseline matrix metalloproteinase (MMP)-8, tissue inhibitor of matrix metalloproteinase (TIMP)-1, myeloperoxidase (MPO)
and C-reactive protein (CRP) concentrations and MMP-8/TIMP-1 ratios in cases with and without incident cardiovascular diseases
(CVDs) or death.
MMP-8 (ng/ml) TIMP-1 (ng/ml) MMP-8/TIMP-1 MPO (ng/ml) CRP (mg/l)
Geometric mean (IQR)
CVD No CVD 30.8 (15.3–58.4) 86.5 (74.8–97.1) 0.35 (0.18–0.69) 14.7 (10.4–19.3) 1.14 (0.52–2.27)
CVD 28.0 (14.0–49.1) 97.7 (83.9–110.2) 0.28 (0.14–0.53) 16.2 (11.2–21.4) 1.96 (0.91–3.88)
p 0.005 <0.001 <0.001 <0.001 <0.001
CAD No CAD 30.6 (15.2–57.8) 86.8 (75.0–97.8) 0.35 (0.17–0.68) 14.8 (10.4–19.5) 1.16 (0.52–2.32)
CAD 29.3 (14.2–51.5) 97.5 (84.0–109.5) 0.30 (0.14–0.55) 15.9 (11.3–20.3) 1.99 (0.92–3.96)
p 0.201 <0.001 0.001 0.007 p<0.001
MI No MI 30.5 (15.2–57.6) 87.1 (75.0–98.0) 0.35 (0.17–0.68) 14.8 (10.4–19.5) 1.17 (0.53–2.34)
MI 31.4 (15.5–56.1) 99.6 (85.6–112.0) 0.31 (0.16–0.59) 16.3 (11.2–21.6) 2.20 (0.97–4.38)
p 0.723 <0.001 0.251 0.015 <0.001
Stroke No stroke 30.7 (15.2–57.7) 87.1 (75.1–98.1) 0.35 (0.17–0.68) 14.8 (10.4–19.4) 1.17 (0.53–2.35)
Stroke 26.4 (13.9–46.1) 99.6 (84.1–113.0) 0.27 (0.14–0.50) 16.9 (11.1–22.9) 2.00 (0.88–3.87)
p 0.003 <0.001 <0.001 <0.001 <0.001
Death No death 30.6 (15.3–57.5) 86.2 (74.8–96.7) 0.35 (0.17–0.68) 14.6 (10.4–19.2) 1.13 (0.52–2.26)
Death 30.1 (14.4–58.5) 100.2 (84.6–112.0) 0.29 (0.14–0.59) 17.0 (11.4–22.1) 2.03 (0.93–4.14)
p 0.592 <0.001 <0.001 <0.001 <0.001
CAD: coronary artery disease; IQR: interquartile range; MI: myocardial infarction.
Mann-Whitney U-test was used for analyses. Statistically significant values (p< 0.05) highlighted (bold). The levels of biomarkers were converted with
natural logarithm for the statistical analyses.
Table 3. Associations of baseline proteinase and inflammatory marker levels with incident cardiovascular disease (CVD) events and
death.
Multivariable adjusted HR (95% CI) per SD



















































CAD: coronary artery disease; CI: confidence interval; CRP: C-reactive protein; HDL: high-density lipoprotein; MI: myocardial infarction; MMP: matrix
metalloproteinase; MPO: myeloperoxidase; SD: standard deviation; TIMP: tissue inhibitor of matrix metalloproteinase.
Estimated with Cox proportional hazards model using age as the time scale, stratified with sex, and adjusted with systolic blood pressure, use of
antihypertensive medication, prevalent diabetes, current smoking, log (total cholesterol), log (HDL cholesterol), education (three categories) and
geographical area (east/west). Statistically significant values are highlighted (bold).
The levels of biomarkers were transformed with natural logarithm for the analyses. SDs for each biomarker are as follows: lnCRP 1.11825, lnMPO
0.61527, lnMMP-8 0.97403, lnMMP-8/TIMP-1 0.22460, lnTIMP-1 0.22306.
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Framingham risk score,23 significantly improved the
discrimination and reclassification of the baseline
model for MI and all-cause death. By including
TIMP-1 concentration in the risk prediction, more indi-
viduals previously classified to be at intermediate risk
(5–20%) could be correctly reclassified: non-cases to a
low-risk category (<5% risk) and cases to a higher risk
category (>20% risk). The clinical NRI produced by
TIMP-1 in the models for MI and mortality was mod-
erate 4.6% (p¼ 0.043) and remarkably high 12.9%
(p< 0.001), respectively. Despite improved prevention
and treatment modalities, CVD still remains the leading
cause of death and its prediction is problematic.
Therefore, novel biomarkers with predictive potential
which are easily obtained from blood samples would
help to screen patients at risk and focus treatment
strategies.
Although TIMP-1 is a potent inhibitor of several
MMPs, many of its functions are independent of this
action. TIMP-1 is a regulator of a broad range of bio-
logical functions, including cell growth, proliferation,
apoptosis, migration and angiogenesis.28,29 Within the
heart and arterial tree, TIMP-1 is expressed by various
cells, i.e. cardiac myocytes, fibroblasts, endothelial cells,
smooth muscle cells and monocytes/macrophages.
These properties provide the basis for, and may
explain, the present results that circulating TIMP-1
concentrations are associated with all the CVD end-
points including mortality. The results we show further
strengthen the findings by others. In the Framingham
offspring cohort, higher plasma TIMP-1 concentrations
were associated with mortality during a 10-year follow
up.30 Cavusoglu et al. described the marked association
and prognostic ability of TIMP-1 levels for mortality
and MI in a two-year follow-up.17 In 1979 patients with
suspected baseline CAD, TIMP-1 was shown to predict
cardiovascular death.18 TIMP-1 was also found to
be an independent predictor of MI, stroke and cardio-
vascular death in patients with stable CAD in a case-
control setting.31 In conclusion, our study completes
these findings by revealing the association of TIMP-1
with incident CAD in a population-based cohort of per-
sons free of CAD at baseline. Amongst all biomarkers,
TIMP-1 concentrations were directly associated with
the highest risk for stroke and death (HR 1.28 and
HR 1.37, per SD increase respectively). Elevated
TIMP-1 concentrations have been reported in patients
with hypertension, poor left ventricular systolic func-
tion and left ventricular hypertrophy, which are
risk factors of stroke and therefore may explain the
significant association.32–34 To support the role in
CAD, MI and stroke, upregulation of TIMP-1 has
been shown at tissue level in coronary thrombi and
ruptured plaques.35,36
MMPs are highly expressed by the inflammatory
cells, mainly neutrophils and macrophages, in athero-
sclerotic lesions ubiquitously in the vascular network
and recognised as prominent regulators of ECM integ-
rity. Our very recent genome-wide (GWAS) data from
similar populations further enlightens the origin of
MMP-8, as complement activation, especially the alter-
native pathway of the cascade, slightly but clearly
Table 4. Improvement of discrimination and reclassification of future myocardial infarction and death by matrix metalloproteinase
(MMP)-8 and tissue inhibitor of matrix metalloproteinase (TIMP)-1.
MI Death
MMP-8 TIMP-1 MMP-8 TIMP-1
C-statistics
Reference risk scorea 0.848 0.848 0.820 0.820
Extended risk scoreb 0.849 0.850 0.821 0.825
Difference 0.001 0.002 0.001 0.006
p-Value 0.496 0.374 0.209 0.004
Improvement
IDI 0.003 (–0.0003–0.006) 0.004 (–0.0002–0.008) 0.00008 (–0.002–0.002) 0.008 (0.003–0.013)
p-Value 0.072 0.039 0.928 0.001
Categorical NRI 0.002 (–0.06–0.06) 0.003 (–0.052–0.057) 0.010 (–0.007–0.026) 0.013 (–0.016–0.042)
p-Value 0.939 0.927 0.252 0.394
Clinical NRI 0.039 (–0.01–0.09) 0.046 (0.001–0.09) 0.052 (0.025–0.079) 0.129 (0.078–0.18)
p-Value 0.127 0.043 <0.001 <0.001
IDI: integrated discrimination improvement; MI: myocardial infarction; NRI: net reclassification improvement.
All cases with prevalent cardiovascular disease (CVD) were excluded. Statistically significant p-values are highlighted (bold).
aBaseline models, Framingham risk factors only.
bBiomarker added to the baseline model. Categorical NRI includes four risk categories (0–5%, 5–10%, 10–20%,> 20%) and clinical NRI considers only
the 5–20% risk category. For the 13-year absolute risk predictions 10 cross validation stratified by sex was used.
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seems to contribute to serum MMP-8 levels.37 This
illustrates the inflammatory aetiology and association
of MMP-8 with CVD. MMP-8 is a key player in the
regulation of atherosclerotic plaque phenotype and
outcome. The elevated levels have been shown to cor-
respond particularly with unstable plaque pheno-
type.9,38 Peeters et al. investigated the levels of MMP-
2, -8 and -9 in a follow-up study, and showed that only
MMP-8 levels were predictive for cardiovascular out-
come.12 We have previously reported that high serum
MMP-8 concentrations are associated with ACS as well
as with incident CVD events.13,15,39 MMP-8 is a pre-
dictor of cardiovascular outcome and left ventricular
remodelling after acute MI.40 Increased plasma
MMP-8 levels have been shown to correlate with the
severity of CAD, and also to associate with vulnerabil-
ity of the carotid artery plaque.9,41 In this study, MMP-
8 was associated with increased risk of CAD events, MI
and mortality. To the best of our knowledge, the
improvement of the baseline risk model for all-cause
mortality by MMP-8 has not been shown earlier.
MMP-8 improved reclassification of intermediate risk
individuals for all-cause death (NRI 5.2%, p<0.001)
and with a borderline level for MI (3.9%, p¼ 0.1).
The present findings support and further extend the
evidence that both MMP-8 and TIMP-1 are important
markers of CVD events and mortality. In terms of
MMP-8/TIMP-1 ratio, the analysis showed a signifi-
cant association with the risk of incident MI. Our
data previously showed that the MMP-8/TIMP-1
ratio is associated increased risk for CVD death.15
Thus, the results further signifies the potential role of
this imbalance in the pathology of acute cardiac events.
MPO and CRP are well known markers of inflam-
mation, and were thus included in the analyses. MPO is
mainly produced by neutrophils in order to kill phago-
cytosed microbial pathogens. However, it can also act
as an inflammatory mediator i.e. by regulating the
activity of MMPs and TIMPs.3,42 It can contribute to
vascular injury and atherosclerosis by causing oxidative
damage.43,44 It has potential prognostic value for a
future cardiac event in healthy individuals and patients
with CAD and ACS.45–47 Use of both MPO and CRP
in the risk assessment has been shown to improve the
prediction model.48 In our study, MPO was associated
significantly only with mortality and stroke. The pre-
dictive potential of MPO has been studied by multiple
groups, but the incremental value in risk assessment
remains open.49
Higher CRP concentrations were significantly
associated with all CVD events and all-cause death,
similarly as observed with TIMP-1. The added
improvement by CRP has been assessed previously in
a large meta-analysis, and the studies using similar NRI
analyses show a moderate improvement.50 Also, its role
in the causal relationship with CAD seems unlikely.51
CRP has been shown to be elevated in conditions, such
as depression and in sick building syndrome.52,53
This illustrates its nature as a non-specific acute
phase protein.
To our knowledge there is no previous study that
investigates the prognostic significance of MMP-8
and TIMP-1 in such a comprehensive and representa-
tive population-based cohort. Furthermore the long
follow-up of 13 years was complete with a high
number of incident events. Limitations of the study
need consideration as well. The population consisted
only of those with Caucasian ethnicity. There are dif-
ferent opinions whether the use of plasma instead of
serum in the analysis of MMP-8 would be optimal,
since the clotting process during the serum preparation
is known to release MMPs from circulating leukocytes.
Therefore, measuring the proteinase from serum also
reflects the potential of the neutrophils to degranulate
and release it, and this degree may depend on genetic
variations.37 Comparison between different studies may
thus be challenging. Nevertheless, serum and plasma
MMP-8 levels have a strong correlation with each
other.15 It is also important to note that there are mul-
tiple other MMPs and several other TIMPs that can be
crucial in the circuitry behind CVD pathology.
In conclusion, this study further elucidates the sig-
nificance of MMP-8 and TIMP-1 in predicting future
CVD events and death. Together, these markers
improve prognostic power to address the cardiac risk
of apparently healthy individuals.
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